Canaccord raises Hinge Health target to $100
Canaccord Genuity analyst Richard Close maintained a Buy rating on Hinge Health (NYSE: HNGE) and raised the price target from $76 to $100. The revision reflects a stronger outlook for the digital health company's growth.
*this image is generated using AI for illustrative purposes only.
Canaccord Genuity analyst Richard Close has maintained a Buy rating on Hinge Health (NYSE: HNGE) while raising the price target for the digital health company. The new target of $100 represents a significant increase from the previous level of $76, reflecting increased confidence in the company's growth trajectory.
Rating and Price Target Update
The decision to upgrade the price target comes as Hinge Health continues to expand its market presence in the digital musculoskeletal care sector. The revised target suggests a potential upside based on the company's operational performance and market position.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $76 |
| New Price Target | $100 |
The analyst's endorsement underscores the firm's positive outlook on Hinge Health's ability to capture market share and deliver value to shareholders.
What specific operational milestones does Hinge Health need to achieve to justify the new $100 price target?
How might increased competition in the digital musculoskeletal care sector impact Hinge Health's ability to capture market share?
What are the potential risks to Hinge Health's growth trajectory that could derail the analyst's bullish outlook?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
